Single-Cell DNA Sequencing of Human Brain Cell Populations: Scientific Advances and Clinical Implications

Abstract

Single-cell DNA sequencing (scDNA-seq) has revolutionized neuroscience by enabling unprecedented resolution in the study of genetic heterogeneity across human brain cell populations. This review details the current landscape of scDNA-seq in human neurobiology, highlighting its epidemiological context, pathophysiological mechanisms, clinical applications, diagnostic value, therapeutic potential, and evolving guidelines. Emphasis is placed on scientific rigor, translational impact, and the integration of scDNA-seq findings into clinical practice for neurologists and healthcare professionals seeking precision medicine approaches to neuropsychiatric disorders and neurodegenerative diseases.

Introduction

The advent of single-cell DNA sequencing has transformed our approach to understanding the human brain, a highly complex organ composed of a diverse array of neuronal and glial subtypes. Unlike bulk sequencing, scDNA-seq provides insight into genetic mosaicism, somatic mutations, and lineage tracing at the level of individual cells, which is crucial for elucidating neurodevelopmental trajectories and disease mechanisms. Recent advances in microfluidics, droplet-based platforms, and bioinformatic pipelines have made high-throughput single-cell genome analysis feasible, propelling the field of neurogenomics toward a new era of personalized medicine. This article aims to synthesize current evidence on the clinical and scientific utility of scDNA-seq in brain research, with a focus on practical implications for diagnosis, prognosis, and therapy.

Epidemiology / Disease Burden

Neurological and psychiatric disorders represent a significant global health burden, affecting millions worldwide and accounting for substantial morbidity and mortality. The heterogeneity of these disorders, such as epilepsy, schizophrenia, autism spectrum disorders, and Alzheimer's disease, is mirrored at the cellular and genetic levels. Traditional approaches have struggled to resolve the mosaicism inherent in brain tissue, limiting the discovery of rare pathogenic variants and cell-specific genetic signatures. The application of scDNA-seq has begun to illuminate the landscape of somatic mutations and clonal diversity within brain cell populations, thus enhancing our ability to stratify risk, predict disease course, and tailor interventions in large, diverse patient cohorts.

Pathophysiology

Human brain development and function are governed by intricate genetic programs subject to both inherited and somatic alterations. scDNA-seq has revealed that neuronal lineages acquire unique somatic mutations during neurogenesis, contributing to cellular diversity and, in some cases, disease susceptibility. For example, studies have identified postzygotic mutations in genes regulating synaptic function and neurodevelopment, linked to focal cortical dysplasia and epileptogenesis. Furthermore, glial cell populations can harbor distinct mutational signatures implicated in gliomagenesis or neuroinflammatory processes. By delineating these cell-type-specific genetic changes, scDNA-seq advances our mechanistic understanding of brain pathophysiology and highlights new cellular targets for intervention.

Risk Factors

Genetic and environmental risk factors converge on the cellular genome, shaping the mutational landscape of each brain cell. scDNA-seq allows for the precise mapping of somatic mutations arising from genotoxic stress, aging, inflammation, and neurotoxins. In neurodegenerative conditions such as Alzheimer's disease, increased somatic mutation burden in neurons and glial cells correlates with disease progression and cognitive decline. Additionally, inherited germline variants may predispose to increased somatic mutagenesis, compounding risk and influencing phenotypic heterogeneity. Recognizing these risk factors at the single-cell level informs both primary prevention and early detection strategies in at-risk populations.

Clinical Features

Clinical phenotypes of neuropsychiatric and neurodegenerative disorders are increasingly understood as consequences of cellular genetic diversity. Mosaic pathogenic variants may underlie focal neurological deficits, treatment-resistant epilepsy, or atypical movement disorders. scDNA-seq enables clinicians to associate specific somatic mutations within defined brain regions with corresponding clinical syndromes, supporting more accurate phenotypic classification and guiding targeted management. The identification of mutational hotspots or clonal expansions in specific neuronal subtypes holds promise for refining clinical taxonomy and informing prognosis.

Diagnosis

The integration of scDNA-seq into diagnostic workflows offers a paradigm shift in neurogenetics. By resolving mosaic variants undetectable in bulk tissue or blood samples, scDNA-seq provides definitive molecular diagnoses in previously unexplained cases of cortical malformations, intellectual disability, and early-onset epilepsies. Recent studies have demonstrated the feasibility of applying scDNA-seq to surgical brain specimens, enabling the identification of driver mutations that inform surgical planning and postoperative management. Moreover, non-invasive approaches, such as cell-free DNA analysis from cerebrospinal fluid, are on the horizon, potentially expanding the utility of scDNA-seq in routine clinical practice.

Treatment & Management

Personalized therapeutic strategies informed by scDNA-seq are emerging as a transformative approach in neurology. For example, the detection of activating mTOR pathway mutations in focal cortical dysplasia has guided the use of targeted mTOR inhibitors in treatment-resistant epilepsy. Similarly, identification of somatic mutations driving glioma subclones supports the rational selection of targeted therapies and immunomodulators. The ability to map clonal evolution and therapeutic resistance at the single-cell level enables dynamic treatment adaptation and longitudinal disease monitoring, paving the way for precision medicine in neuro-oncology and beyond.

Recent Advances / Emerging Therapies

Technological innovations, including improved whole-genome amplification, high-throughput sequencing, and sophisticated bioinformatics pipelines, have enhanced the sensitivity and specificity of scDNA-seq. Emerging therapies are being tailored to the unique mutational profiles uncovered by single-cell analyses, such as gene editing tools (CRISPR/Cas systems) directed at pathogenic somatic variants in defined cell populations. Ongoing clinical trials are exploring the use of scDNA-seq to stratify patients for immunotherapies and targeted agents, particularly in brain tumors and refractory epilepsy. Collaborative efforts, such as the Human Cell Atlas, are establishing reference maps that will inform both research and clinical applications for years to come.

Guideline Recommendations

Leading neurological and genetic societies now acknowledge the value of single-cell technologies in research and clinical care. Consensus guidelines recommend scDNA-seq for the workup of refractory neurodevelopmental disorders, unexplained focal epilepsies, and complex brain tumors when conventional diagnostics are inconclusive. Multidisciplinary teams, including neurologists, geneticists, pathologists, and bioinformaticians, are essential for the appropriate interpretation and translation of scDNA-seq findings. Ongoing guideline development emphasizes the need for standardized protocols, robust data sharing, and longitudinal patient follow-up to maximize the clinical impact of single-cell genomics.

Conclusion

Single-cell DNA sequencing represents a significant advance in our ability to interrogate the genetic architecture of human brain cell populations. By revealing the cellular and molecular underpinnings of neurological disease, scDNA-seq holds promise for improving diagnostic accuracy, informing individualized treatment, and advancing precision medicine. Continued technological improvement, integration into clinical practice, and adherence to evolving guidelines are essential to realize the full potential of this transformative technology for patients with complex brain disorders.